The Guideline
The Guideline
- 1: Development and Implementation
- 2: Working Definition
- 3: Prevention
- 4: Evaluation of Ventricular Dysfunction
- 5: Asymptomatic Patients
- 6: Nonpharmacologic Management
- 7: Reduced Ejection Fraction
- ACE Inhibitors
- Beta Adrenergic Receptor Blockers
- Implantation of Cardiac Pacemakers in Patients With Baseline Bradycard
- Angiotensin Receptor Blockers
- Aldosterone Antagonists
- Renin Inhibitors
- Oral Nitrates and Hydralazine
- Optimal Use of Multi-Drug Therapy
- Diuretic Therapy
- Digoxin
- Anticoagulation and Antiplatelet Drugs
- Amiodarone Therapy
- Polyunsaturated Fatty Acids
- References
- 8: Disease Management, Advance Directives, End-of-Life Care
- 9: EP Testing and Use of Devices
- 10: Surgical Approaches
- 11: Preserved LVEF
- 12: Acute Decompensated HF
- 13: Ischemic Heart Disease
- 14: Hypertension and HF
- 15: HF in Special Populations
- 16: Myocarditis
- 17: Genetic Evaluation
About the Guideline
News & Downloads
Legal Information